New biologics, expanding indications, and rapid growth in GLP-1 therapies are bringing effective treatments to unprecedented numbers of patients. Yet this progress is exposing a constraint – manufacturing capacity.
The next major bottleneck may not be scientific innovation or device design, but the ability to industrialise, validate, and manufacture devices reliably at the volumes the market requires.
Demand outpacing industrial scale
GLP-1 therapies provide the clearest illustration. Although oral formulations will become more prominent, they are more likely to expand the overall market than replace injectable therapies entirely.
Even if the injectable share of the GLP-1 market fell to 60% by 2035, the number of patients using injectable products could still increase approximately threefold. That would create significant additional demand for pens, autoinjectors, primary containers and associated components, all made by Quvara.
The effect extends beyond obesity and diabetes. GLP-1 programmes compete for parts of the same specialist supplier ecosystem, precision-moulding capacity, glass primary packaging and automated assembly resources required by monoclonal antibodies and rare-disease injectables. Rapid growth in one category can therefore tighten capacity across otherwise unrelated therapies.
Companies also want greater device choice, regional supply security and flexibility across launch and volume scenarios.
The challenge is that manufacturing capacity cannot be created instantly.
The fallacy of turnkey device capacity
Drug-delivery manufacturing requires far more than available factory space. It depends on specialist tooling and automation, appropriate cleanroom infrastructure, validated processes, experienced personnel, and mature quality systems.
Material selection, component tolerances, assembly processes and interaction with the primary container can all affect manufacturability and performance. A successful prototype does not automatically become a device that can be manufactured consistently at commercial scale.
Taken together, specification, manufacture, commissioning and validation of hardened multi-cavity tooling and custom high-speed assembly can require 18 to 24 months or longer. If capacity is considered only at an advanced development stage, the available options may already be severely constrained.
Forecast uncertainty adds another complication. A solution designed for modest launch volumes may struggle if demand accelerates, while infrastructure built around an optimistic forecast may become inefficient if adoption is slower. Manufacturing strategy must accommodate both growth and uncertainty.
Recent disruption has also challenged the assumption that concentrated global supply chains will always provide the most dependable or cost-effective solution. Geopolitical tension, freight disruption, energy volatility and regionalisation have made resilience a strategic concern.
For regulated products, transferring manufacture after a disruption is rarely straightforward. Tooling, processes and suppliers may be product-specific, while changes can require technical assessment, revalidation and regulatory approval.
This raises an important question: has the supply chain been optimised for lowest cost at the expense of resilience?
A nominal second source provides limited protection without validated tooling, reserved capacity or the practical ability to begin production. Alternative locations offer little security if transfer would take years rather than months. Resilience must be designed into the manufacturing architecture before it is needed.
De-risking supply chains through upstream engagement
The traditional sequence (develop the drug, select the device and then identify a manufacturer) is therefore increasingly risky. Manufacturing considerations should form part of product and device strategy from an earlier stage.
Companies need to establish whether the proposed architecture can support launch and peak volumes; whether manufacturability has been evaluated alongside device functionality; what tooling, automation and validation will be required; and whether production could be transferred or duplicated following disruption.
Early engagement does not require an immediate commitment to large-scale capital investment. It allows realistic pathways and technical and commercial gates to be defined. Early clinical or launch volumes may use lower-capital methods, with automation introduced as demand becomes clearer.
One response is to work with established manufacturing platforms that combine available capacity with proven industrialisation expertise. At Quvara Medical, that means more than 30 years of validated production experience, established UK cleanroom, moulding, and automated-assembly infrastructure, and support from early manufacturability assessment through transfer, validation and high-volume manufacture. Capacity can be developed progressively, aligning investment with demand while avoiding the delay and risk of creating an entirely new manufacturing environment.
Capacity as a strategic moat
The drug-delivery industry has traditionally viewed manufacturing capacity as something secured after the principal product decisions have been made. That approach is becoming harder to sustain.
In a market shaped by rapidly expanding demand and continuing uncertainty, industrial capacity is a strategic asset. Companies that consider manufacturability, scalability and supply-chain optionality early will be better placed to respond to successful launches, changing forecasts and external disruption.
Innovation will remain fundamental to drug delivery. But its commercial and clinical value can only be realised if products can be manufactured reliably, compliantly and at the required scale.
“Which device should we choose?” is therefore no longer the only defining question. Companies must also ask: “Who can help us industrialise it reliably in an uncertain world?”
